KRRO (Korro Bio) LT-Debt-to-Total-Asset: 0.22 (As of Mar. 2026)


KRRO Korro Bio Inc KRRO
6 GF Score
Price $13.20
! 4 Warning Signs
View Full Analysis

What is Korro Bio LT-Debt-to-Total-Asset?

Korro Bio KRRO +3.90% 6 LT-Debt-to-Total-Asset is 0.22 as of Mar. 2026. GuruFocus rates KRRO with a GF Score™ of 6/100. The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Korro Bio's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.22.

Korro Bio's long-term debt to total assets ratio increased from Mar. 2025 (0.21) to Mar. 2026 (0.22). It may suggest that Korro Bio is progressively becoming more dependent on debt to grow their business.

Korro Bio  (NAS:KRRO) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Korro Bio LT-Debt-to-Total-Asset Related Terms

Korro Bio LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Korro Bio's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Korro Bio LT-Debt-to-Total-Asset Chart

Korro Bio Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
0.00 0.00 0.14 0.19 0.36

Korro Bio Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.23 0.26 0.36 0.22
KRRO
6GF Score
Korro Bio Inc KRRO
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Korro Bio LT-Debt-to-Total-Asset Calculation

Korro Bio's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=40.814/113.506
=0.36

Korro Bio's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=40.084/183.622
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.22 mean?
Korro Bio (KRRO) has a LT-Debt-to-Total-Asset of 0.22 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Korro Bio and its competitors.
Is Korro Bio's LT-Debt-to-Total-Asset too high?
Korro Bio's current LT-Debt-to-Total-Asset is 0.22. Overall, Korro Bio has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Korro Bio's LT-Debt-to-Total-Asset compare to LENZ and ANTX?
Korro Bio's LT-Debt-to-Total-Asset of 0.22 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Korro Bio and its competitors. Korro Bio's current LT-Debt-to-Total-Asset is 0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Korro Bio stock overvalued right now?
Korro Bio (KRRO) has a current LT-Debt-to-Total-Asset of 0.22. The current LT-Debt-to-Total-Asset is 0.22. Korro Bio's overall GF Score™ is 6/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Korro Bio (KRRO), the current LT-Debt-to-Total-Asset is 0.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Korro Bio Business Description

Address 60 First Street, 2nd Floor, Suite 250, Cambridge, MA, USA, 02141
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
6GF Score

Get the complete analysis for KRRO

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.20
Price